Related Experiment Video
Updated: Aug 13, 2025

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal
Connor Enright1, Elizabeth Thomas2,3, David R Saxon2,3
1Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Abstract:
Despite professional society guidelines recommending that obesity be treated as a chronic disease by emphasizing the use of lifestyle modification in conjunction with pharmacotherapy, antiobesity medications are uncommonly prescribed in most clinical practices. The recent Food and Drug Administration approval of semaglutide 2.4 mg weekly to treat obesity-as well as other forthcoming advancements in diabetes and antiobesity medications-highlights the potential of pharmacotherapy to significantly augment weight loss efforts. In this Expert Endocrine Consult, we review the evolving role of antiobesity pharmacotherapy in clinical practice and suggest a framework for the use of these medications.
Related Concept Videos
Obesity
Atherosclerosis III: Management
Antidepressant Drugs: MAOIs and Other Agents
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Therapy
Antianxiety Medications
Hypertension IV: Drug Therapy and Lifestyle Modifications

